Atmospheric pressure cold plasma treatment for moderate-to-severe athlete's foot

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with moderate-to-severe interdigital tinea pedis confirmed by KOH microscopy will receive active cold atmospheric plasma (CAP), a sham CAP procedure, or standard care to compare outcomes. Disease severity is defined by lesion scores for erythema, desquamation, and pruritus, and participants must meet predefined score thresholds to enroll. The study will measure fungal clearance, symptom improvement, recurrence, and safety over the treatment and follow-up period. Treatments are delivered to affected foot areas and safety monitoring will track local skin reactions and any adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age between 18 and 70 years, irrespective of sex.
* Clinical diagnosis of interdigital tinea pedis (non-hyperkeratotic type), with or without extension to other areas, of moderate to severe intensity, defined as follows: target lesion(s) will have an erythema score of ≥2 and either a desquamation or pruritus score of ≥2, with a total score ≥4 (using a 0-3 scale for each item).
* Positive direct potassium hydroxide (KOH) microscopic examination for dermatophytes.
* Women of childbearing potential will agree to use effective contraception throughout the study period.
* Written informed consent will be obtained prior to enrollment.

Exclusion Criteria:

* Severe bacterial infection or other dermatological conditions that may interfere with study assessments.
* Serious cardiac, hepatic, or renal diseases, diabetes mellitus, or major psychiatric disorders.
* Systemic corticosteroid or immunosuppressant use within the past 3 months.
* Systemic antifungal agents within the past 2 months or topical antifungal agents within the past 2 weeks.
* Pregnancy or breastfeeding.

Where it's running

• The 989th Hospital of Chinese People's Liberation Army Joint Logistic Support Force
  Luoyang, Henan, China Recruiting

Study contacts

• Principal investigator: Lin Tao, MM — Shenyang Medical College
• Study coordinator: Yun-En Liu, MD
• Email: lye9901@163.com
• Phone: 86-24-62215130

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dermatophyte antifungal susceptibility in Faisalabad: terbinafine and itraconazole MICs

  This study tests how common skin fungus infections in Faisalabad respond to terbinafine and itraconazole by measuring the lowest drug levels that stop growth in patient samples.

  Recruiting Allied Hospital Faisalabad · Faisalabad, Punjab Province · NCT07898475

• ZYG24004 in tinea pedis: a topical film-forming treatment tested for safety and early effectiveness

  A tiny topical medication (ZYG24004) is being tested in adults with athlete's foot to see if it is safe and tolerable and to get a first look at its effect against the fungus.

  Recruiting Phase 1 Sinomune Pharmaceutical Co., Ltd · Beijing, Beijing Municipality · NCT07668999

• 1% tolnaftate stick treatment for tinea pedis (athlete's foot)

  This study will test three different 1% tolnaftate stick formulas to see if they are safe and help people aged 16 and older with tinea pedis (athlete's foot).

  Recruiting at 2 sites Phase 2 Propedix, Inc. · Framingham, Massachusetts and 1 other locations · NCT07245667

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.